This week we spoke to George Tziras, the new CEO of Small Pharma, about the company’s pipeline and priorities against the backdrop of a challenging economic context. The London-based psychedelic drug developer is almost exclusively focused on the short-acting psychedelic DMT, with its lead candidate (SPL026) designed to be administered alongside talk therapy for the treatment of Major Depressive…
